Prof. Dr. Urs Eriksson
University of Zurich, Zürich, Switzerland
'%3e%3cpath%20d='M22.1642%2019.0924C21.7317%2018.068%2021.1041%2017.1375%2020.3163%2016.3527C19.5309%2015.5656%2018.6006%2014.9381%2017.5766%2014.5048C17.5674%2014.5002%2017.5582%2014.4979%2017.5491%2014.4933C18.9774%2013.4616%2019.9059%2011.7811%2019.9059%209.88504C19.9059%206.74408%2017.3611%204.19922%2014.2201%204.19922C11.0792%204.19922%208.53429%206.74408%208.53429%209.88504C8.53429%2011.7811%209.46282%2013.4616%2010.8912%2014.4956C10.882%2014.5002%2010.8728%2014.5025%2010.8636%2014.5071C9.83652%2014.9404%208.91487%2015.5617%208.1239%2016.355C7.33685%2017.1404%206.70933%2018.0707%206.276%2019.0947C5.85031%2020.0972%205.62072%2021.172%205.59967%2022.2609C5.59905%2022.2853%205.60335%2022.3097%205.61229%2022.3325C5.62123%2022.3553%205.63465%2022.376%205.65174%2022.3935C5.66883%2022.4111%205.68926%2022.425%205.71182%2022.4345C5.73437%2022.444%205.7586%2022.4489%205.78308%2022.4489H7.15868C7.25956%2022.4489%207.3398%2022.3686%207.3421%2022.2701C7.38795%2020.5001%208.09868%2018.8425%209.35506%2017.5861C10.655%2016.2862%2012.3814%2015.5709%2014.2201%2015.5709C16.0588%2015.5709%2017.7852%2016.2862%2019.0852%2017.5861C20.3415%2018.8425%2021.0523%2020.5001%2021.0981%2022.2701C21.1004%2022.3709%2021.1807%2022.4489%2021.2815%2022.4489H22.6571C22.6816%2022.4489%2022.7058%2022.444%2022.7284%2022.4345C22.751%2022.425%2022.7714%2022.4111%2022.7885%2022.3935C22.8056%2022.376%2022.819%2022.3553%2022.8279%2022.3325C22.8369%2022.3097%2022.8412%2022.2853%2022.8406%2022.2609C22.8176%2021.165%2022.5907%2020.0989%2022.1642%2019.0924ZM14.2201%2013.8284C13.1678%2013.8284%2012.1773%2013.418%2011.4322%2012.6729C10.6871%2011.9278%2010.2767%2010.9374%2010.2767%209.88504C10.2767%208.83271%2010.6871%207.84227%2011.4322%207.09715C12.1773%206.35204%2013.1678%205.94165%2014.2201%205.94165C15.2724%205.94165%2016.2629%206.35204%2017.008%207.09715C17.7531%207.84227%2018.1635%208.83271%2018.1635%209.88504C18.1635%2010.9374%2017.7531%2011.9278%2017.008%2012.6729C16.2629%2013.418%2015.2724%2013.8284%2014.2201%2013.8284Z'%20fill='%238590A2'/%3e%3c/g%3e%3c/svg%3e)
Co-authors
Following
Followers
Research Focus & Metrics
Explore full metrics on Scilit
Academic Career Length
34Years (1993-Present)
(Calculated once Scilit publication data is synced: current year − year of first publication + 1)
Representative Publications
View All Publications7 April 2021 in European Heart Journal
Journal Article
PGPablo Garcia-Pavia
Pablo Garcia-PaviaCRClaudio Rapezzi
Claudio Rapezzi
YAYehuda Adler
Yehuda Adler
MAMichael Arad
Michael Arad
CBCristina Basso
Cristina BassoALAleš Linhart
Aleš Linhart +18
Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the hereditary forms or as a consequence of acquired conditions. Thanks to advances in imaging techniques and the possibility of achieving a non-invasive diagnosis, we now know that cardiac amyloidosis is a more frequent disease than traditionally considered. In this position paper the Working Group on Myocardial and Pericardial Disease proposes an invasive and non-invasive definition of cardiac amyloidosis, addresses clinical scenarios and situations to suspect the condition and proposes a diagnostic algorithm to aid diagnosis. Furthermore, we also review how to monitor and treat cardiac amyloidosis, in an attempt to bridge the gap between the latest advances in the field and clinical practice.
11 February 2002 in Archives of internal medicine (1960)
Journal Article
CMChristian Mueller
Christian MuellerGBGerd Buerkle
Gerd Buerkle
HBHeinz J. Buettner
Heinz J. Buettner
JPJens Petersen
Jens Petersen
APAndré P. Perruchoud
André P. Perruchoud
HRHelmut Roskamm
Helmut Roskamm
+2
PREVENTION OF disease should always be the highest priority, particularly if there is no effective therapy and the disease is iatrogenic. The administration of radiographic contrast agents remains an important cause of hospital-acquired acute renal failure, which contributes to morbidity and mortality during hospitalization, prolongs hospital stay, and increases the incidence of chronic end-stage renal disease and costs of health care.1-5
16 November 2003 in Nature Medicine
Journal Article
Urs ErikssonRRRomeo Ricci
Romeo RicciLHLukas Hunziker
Lukas HunzikerMKMichael O Kurrer
Michael O Kurrer
GOGavin Y Oudit
Gavin Y Oudit
JPJosef M Penninger
Josef M Penninger +4
1 November 2016 in JACC
Journal Article
SHStephane Heymans
Stephane Heymans
Urs ErikssonJLJukka Lehtonen
Jukka Lehtonen
LCLeslie T. Cooper
Leslie T. Cooper1 April 2013 in Immunity
Journal Article
TSThimoteus Speer
Thimoteus SpeerLRLucia Rohrer
Lucia Rohrer
PBPrzemysław Błyszczuk
Przemysław BłyszczukRSRukshana Shroff
Rukshana ShroffKKKira Kuschnerus
Kira Kuschnerus
ULUlf Landmesser
Ulf Landmesser
+20
26 June 2017 in European Heart Journal
Journal Article
Alida CaforioYAYehuda Adler
Yehuda Adler
CACarlo Agostini
Carlo AgostiniYAYannick Allanore
Yannick Allanore
AAAris Anastasakis
Aris Anastasakis
ALAles Linhart
Ales Linhart
+20
Systemic immune-mediated diseases (SIDs) include autoimmune and autoinflammatory diseases (AD) affecting at least two-organ systems.1 Autoinflammatory diseases refer to a growing family of conditions characterised by episodes of unprovoked inflammation in the absence of high autoantibody titres or auto reactive T lymphocytes, reflecting a primary innate immune system dysfunction.1 Conversely, autoimmune diseases are characterised by aberrant B, T and dendritic cell responses, leading to a break in tolerance against self-antigens, with predominantly cell-mediated or autoantibody-mediated responses in genetically susceptible individuals.2–11 Autoantibodies (AAbs), when detectable, can promote inflammatory responses via immune complex formation and may directly affect target organ function,10 e.g. resulting, in cardiac autoimmunity, in electrical disturbance, cardiomyocyte dysfunction or loss and heart failure.12–15 However, a dichotomous classification does not reflect clinical evidence and a continuum from purely autoinflammatory to purely autoimmune diseases should be considered (Figure 1).1
About Me
Urs Eriksson, born September 1th 1964, is affiliated with the faculty of Medicine of the University of Zurich and Professor of Cardiology.
Urs Eriksson`s research interests are cardiac inflammation and arrhythmogenesis. Professor Eriksson has authored many highly cited research articles. He acts as an expert reviewer for various international biomedical journals, as well as for several international research funding agencies. Moreover, he refers to several offices in professional societies. Professor Eriksson committed himself to educational and research activities for the international community of cardiologists.
Urs Eriksson graduated in 1988 at the Swiss Federal Institute of Technology in Zurich (MSc ETH) and in 1995 as Medical Doctor (MD) at the University of Zurich. Urs Eriksson attained board certifications in Cardiology, Internal Medicine, and Critical Care Medicine. From 2004 until 2010, Urs Eriksson held a Swiss National Foundation professorship. In 2010, he was assigned clinical director of the Department of Medicine, and in 2013, Executive Board member and Chief Medical Officer of the GZO Zurich Regional Health Center in Wetzikon, Switzerland until Mrch 2025. In 2018, he achieved the Diploma in Advanced Studies in Cardiac Arrhythmia Management from the University of Maastricht, Netherlands.